NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2024

Conditions

Melanoma Stage IIIMelanoma Stage IVMelanoma

Interventions

DRUG

Dabrafenib

Observational stusy. No intervention is planned

DRUG

Trametinib

Observational stusy. No intervention is planned

Trial Locations (15)

114578

RECRUITING

N.N. Blokhin Russian Cancer Research Center, Moscow

129090

RECRUITING

Moscow City Clinical Oncology Hospital No. 1, Moscow

153040

RECRUITING

Ivanovo Regional Oncological Dispensary, Ivanovo

344006

RECRUITING

Rostov Regional Oncological Dispensary, Rostov-on-Don

392000

RECRUITING

Tambov Regional Oncological Clinical Dispensary, Tambov

426009

RECRUITING

Republican Clinical Oncological Dispensary named after Sergei Grigoryevich Primushko Ministry of Health of the Udmurt Republic, Izhevsk

428020

RECRUITING

Republican Clinical Oncology Center of Chuvashia, Cheboksary

430032

RECRUITING

"State Budget Health Institution of the Republic of Mordovia Republican Oncological Dispensary", Saransk

614066

RECRUITING

Perm Regional Oncological Dispensary, Perm

620043

NOT_YET_RECRUITING

Sverdlovsk Regional Oncology Center, Yekaterinburg

644013

RECRUITING

Omsk Regional Clinical Oncology Center, Omsk

656000

RECRUITING

Altai Regional Oncological Dispensary, Barnaul

660133

RECRUITING

"KGBUZ Krasnoyarsk regional clinical oncological dispensary named after A.I. A.I. Kryzhanovsky", Krasnoyarsk

664035

RECRUITING

Irkutsk Regional Oncological Dispensary, Irkutsk

693010

RECRUITING

GBUZ Yuzhno-Sakhalinsk oncologic dispensary, Yuzhno-Sakhalinsk